RP2D in Early-Phase Clinical Trials: Determining the Optimal Dose for Phase 2 Studies
Determining the Recommended Phase 2 Dose (RP2D) is one of the most critical steps in early-phase clinical trials. It bridges the gap between initial safety testing and broader efficacy studies, ensuring that only the most appropriate and tolerable dose moves forward. RP2D selection goes beyond simply identifying the maximum tolerated dose; it requires evaluating safety […]